VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women

ClinicalTrials.gov ID: NCT00453089

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00453089. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Dose Escalation Clinical Trial to Assess Safety and Efficacy of VG101 to Treat the Symptoms of Vulvar and Vaginal Atrophy in Post-Menopausal Women

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least one menopausal vaginal symptom, vaginal pH \> 5.0 and \> 20% parabasal vaginal epithelial cells.

Study identification

NCT ID: NCT00453089
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Bionovo; Industry
Enrollment: 40 participants

Conditions and interventions

Conditions

Interventions

VG101 Drug

Drug

Eligibility (public fields only)

Age range: 45 Years to 65 Years
Sex: Female
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2012 (Type not available)
Primary completion: Jun 2013 (Estimated)
Completion: Aug 2013 (Estimated)
Last update posted: Feb 8, 2012

2012 – 2013

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
University of Alabama, Birmingham	Birmingham	Alabama	35294	—
University of California, San Francisco	San Francisco	California	94115	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00453089, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 8, 2012 · Synced Nov 15, 2026